Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07639021 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 230 to confirmed 233
    • Primary and study completion dates: Jul 12, 2027 to Jun 14, 2027
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 25 of 25 sites
  2. Recruitment opened
    • Site details revised at 25 of 25 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Trial Details
NCT Number NCT07639021
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 233 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov